logo-loader
viewe-Therapeutics plc

UPDATE: e-Therapeutics' early data encourages

Early and very limited results from e-Therapeutics’ (LON:EXT) phase I trial of cancer drug candidate ETS2101 have so far revealed no “dose limiting toxicities” or other adverse effects.

medical_chart350_50d08b00baf93.jpg

---Adds comments from the CFO---

Early and very limited results from e-Therapeutics’ (LON:EXT) phase I trial of cancer drug candidate ETS2101 have thus far revealed no “dose limiting toxicities” or other adverse effects.

So far, 12 patients have been given low doses of the treatment in phase I studies, which are designed to test the safety and tolerability. The amount administered will be increased over time.

Researchers are assessing two groups – one with primary or secondary brain cancer, the other with solid tumours. Both sets of patients have advanced cancer.

The former, which will ultimately enrol 24 patients, remains on track to report its findings in the final quarter of 2103, while the latter, which will take in 45 patients, is expected to yield results in the first three months of 2014.

The company revealed that some patients have completed “multiple cycles of treatment with ETS2101 and a number continue to be treated having received up to 11 weekly doses”.

Professor Santosh Kesari, of the Moores Cancer Center in California, is the investigator leading the brain cancer study.

He said: “We are delighted to be evaluating the novel anti-cancer agent ETS2101 at our centre.

“Though we have so far exposed patients only to relatively low doses of the drug, we are reassured that the findings to date suggest good tolerability as we move to enrol additional patients at increasing doses.”

Daniel Elger, chief financial officer, said there had been no serious side effects from the first two levels of dosing.

He said phase I trials are primarily about safety and establishing the maximum tolerated dose of the drug, although they also look for preliminary evidence of whether the drug has effects against the cancer.

“It’s good news that patient enrolment is on schedule as this gives us confidence we can meet the timelines we’ve given for reporting results from the trials.” Elger said.

 

Quick facts: e-Therapeutics plc

Price: 3.25 GBX

AIM:ETX
Market: AIM
Market Cap: £8.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics plc named herein, including the promotion by the Company of e-Therapeutics plc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

RNS

Holding(s) in Company

on 11/08/2019

Holding(s) in Company

on 10/29/2019

Holding(s) in Company

on 10/28/2019

Holding(s) in Company

on 10/28/2019

Holding(s) in Company

on 10/28/2019

Half-year Report

on 10/07/2019

Holding(s) in Company

on 09/17/2019

2 min read